Table 3.
Frequency of specific vaccinations after presentation of the project at school in 748 subjects who completed the study, according to randomization group.a
| Overall (n = 748) | No intervention (n = 284) | Web-site only (n = 224) | Web-site + lesson (n = 238) | ||
|---|---|---|---|---|---|
| Vaccination | n (%) | n (%) | n (%) | n (%) | p-value |
| Tdap booster | 262 (35.1) | 15 (5.3) | 99 (44.2) | 148 (62.2) | <0.001 |
| MenACYW vaccine | 182 (24.4) | 3 (1.1) | 52 (23.2) | 127 (53.4) | <0.001 |
| HPV vaccine | 44 (5.9) | 17 (6.0) | 9 (4.0) | 18 (7.6) | 0.27 |
| MenB vaccine | 41 (5.5) | 0 (0.0) | 0 (0.0) | 41 (17.2) | <0.001 |
| MenC vaccine | 9 (1.2) | 1 (0.3) | 4 (1.8) | 4 (1.7) | NE |
| Chickenpox vaccine | 2 (0.3) | 0 (0.0) | 0 (0.0) | 2 (0.8) | NE |
| Influenza vaccine | 2 (0.3) | 1 (0.3) | 0 (0.0) | 1 (0.4) | NE |
a
Two subjects (in group A) had follow-up contact but did not answer questions on vaccinations performed during follow-up
HPV: human papillomavirus; MenACYW: conjugated meningococcal ACYW vaccine; MenB: meningococcal B vaccine; Tdap: tetanus, diphtheria, acellular pertussis; and NE: not estimable because of the small number of vaccinated subjects.